Arima Genomics
2 known investors
Arima Genomics develops DNA-based cancer diagnostics that combine genomic sequence with structural information to detect cancer-driving mutations and rearrangements. The company delivers clinical testing services (Aventa) for oncologists and partners with biopharma teams to identify therapeutic biomarkers.
BiotechDigital HealthMedical Devices
Investors · 2
Non-dilutive funding · 10 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $2.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $2.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $2.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.8M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $290.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $274.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2015 | $729.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.